Thomas J Scriba
Affiliation: University of Cape Town
Country: South Africa
- Scriba T, Tameris M, Smit E, van der Merwe L, Hughes E, Kadira B, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med. 2012;185:769-78 pubmed publisher..MVA85A was safe and immunogenic in persons with HIV and/or M.tb infection. These results support further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations. ..
- Mearns H, Geldenhuys H, Kagina B, Musvosvi M, Little F, Ratangee F, et al. H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. Vaccine. 2017;35:132-141 pubmed publisher....
- Moguche A, Musvosvi M, Penn Nicholson A, Plumlee C, Mearns H, Geldenhuys H, et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe. 2017;21:695-706.e5 pubmed publisher..Our findings suggest that different vaccination strategies will be required to optimize protection mediated by T cells recognizing antigens expressed at distinct stages of Mtb infection. ..